Trial Profile
Phase II trial of Ifenprodil for COVID-19 infection
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 28 Nov 2020
Price :
$35
*
At a glance
- Drugs Ifenprodil (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Sponsors Algernon Pharmaceuticals
- 13 Nov 2020 According to an Algernon Pharmaceuticals media release, the company will be providing an update on its Ifenprodil Phase 2 human clinical studies presented by Christopher J. Moreau, CEO and Dr. Mark Williams, CSO and hosted by Dr. KSS MD PhD. The BioPub webcast will be held on November 13, 2020
- 06 Apr 2020 New trial record
- 02 Apr 2020 According to an Algernon Pharmaceuticals media release, the company is working to prepare all documentation for an ethics approval submission in Australia, which will be filed shortly.